Leukemia stem cells in 2010: current understanding and future directions [0.03%]
2010年白血病干细胞研究现状及未来方向展望
Michael W Becker,Craig T Jordan
Michael W Becker
Myeloid leukemias are clonal disorders originating in a primitive multipotential hematopoietic cell and characterized by aberrant proliferation, differentiation and maturation of leukemic progenitors and precursor cells. These diseases are ...
Anuj Mahindra,Teru Hideshima,Kenneth C Anderson
Anuj Mahindra
Multiple myeloma (MM) is a clonal B-cell malignancy characterized by the aberrant expansion of plasma cells within the bone marrow, as well as at extramedullary sites. Decades of scientific research are now beginning to unravel the intricat...
Jesús F San-Miguel
Jesús F San-Miguel
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies [0.03%]
来那度胺为基础的新型联合疗法在多发性骨髓瘤未来药物开发中的应用概述
Gareth Morgan
Gareth Morgan
The introduction of thalidomide, lenalidomide, and bortezomib has changed the way that multiple myeloma (MM) is treated and has greatly improved survival outcomes. These novel agents are often used in combination with conventional drugs, su...
Meletios-Athanassios Dimopoulos,Evangelos Terpos
Meletios-Athanassios Dimopoulos
Lenalidomide is a novel immunomodulatory agent with a unique dual mechanism of action: its tumoricidal effect leads to direct tumor cell death, and its immunomodulatory effect keeps the tumor in remission. Phase III clinical trials have dem...
Faith Davies,Rachid Baz
Faith Davies
New effective strategies are required that specifically address the challenges of multiple myeloma (MM) treatment, namely, disease recurrence, immunosuppression, and treatment-related toxicities. Recent preclinical and clinical findings sug...
Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview [0.03%]
来那度胺的作用机制对长期控制多发性骨髓瘤的意义：介绍与概要概述
Jesús F San-Miguel
Jesús F San-Miguel
Fabio P S Santos,Srdan Verstovsek
Fabio P S Santos
Physicians treating patients with the classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) (polycythemia vera [PV], essential thrombocythemia [ET] and primary myelofibrosis [PMF]) traditionally had few therapeutic d...
Michael Hallek,Natali Pflug
Michael Hallek
The management of chronic lymphocytic leukaemia is currently undergoing profound changes. Several drugs like bendamustine, alemtuzumab and rituximab have recently been approved for CLL treatment by regulatory agencies. New and very promisin...
Matthew L Smith,Robert K Hills,David Grimwade
Matthew L Smith
Acute myeloid leukaemia (AML) is one of the most common haematological malignancies and is increasing in frequency due to an ageing population. Whilst remission will be achieved in up to 80% of those receiving intensive chemotherapy, the ma...